Risk factors for colorectal cancer in IBD patients
https://doi.org/10.31146/1682-8658-ecg-205-9-140-146
Abstract
A characteristic feature of inflammatory bowel diseases (IBD) is an increased risk of neoplasia and colorectal cancer (CRC). The introduction of screening programs, as well as modern advances in therapy and endoscopic technologies, awareness of the risk factors of IBD-associated CRC will contribute to reducing the frequency of this dangerous complication of IBD. The presented review describes epidemiological data on the incidence of IBD-associated CRC, established risk factors for CRC, as well as modern methods of prevention, screening and early diagnosis. Literature search was conducted in PubMed and Google Scholar systems by keywords: inflammatory bowel diseases, ulcerative colitis, Crohn’s disease, colorectal cancer, risk factors, screening, endoscopy, dysplasia.
About the Authors
G. R. Bikbavova
Omsk State Medical University
Russian Federation
Russian Federation
M. A. Livzan
Omsk State Medical University
Russian Federation
Russian Federation
M. M. Fedorin
Omsk State Medical University
Russian Federation
Russian Federation
References
1. Kaser A., Zeissig S., Blumberg R. S. Inflammatory bowel disease. Annu Rev Immunol. 2010;28:573-621. doi:10.1146/annurev-immunol-030409-101225.
2. Borg-Bartolo S.P., Boyapati R. K., Satsangi J., Kalla R. Precision Medicine in Inflammatory Bowel Disease: Concept, Progress and Challenges. F1000Research. 2020;9: F1000 Faculty Rev-54. doi:10.12688/f1000research.20928.1.
3. Bikbavova G. R., Livzan M. A., Fedorin M. M. Prevention of colorectal cancer in patients with inflammatory bowel disease. Farmateka. 2021;28(7):8-14. (In Russ.). doi:10.18565/pharmateca.2021.7.8-14. @@Бикбавова Г. Р., Ливзан М. А., Федорин М. М. Профилактика колоректального рака у больных воспалительными заболеваниями кишечника. Фарматека. 2021;28(7):8-14. doi:10.18565/pharmateca.2021.7.8-14.
4. Brief algorithms of patient management at the stage of primary health. Moscow, Vidox, 2019. (In Russ.). URL: https://org.gnicpm.ru/wp-content/uploads/2020/03/kratkie-algoritmy-poslednie.pdf @@Краткие алгоритмы ведения пациентов на этапе оказания первичной медико- санитарной помощи: Пособие для врачей- терапевтов. - Москва: Видокс, 2019. URL: https://org.gnicpm.ru/wp-content/uploads/2020/03/kratkie-algoritmy-poslednie.pdf.
5. Belousova E. A., Abdulganiyeva D. I., Alexeyeva O. P., et al. Social-demographic characteristics, current features and treatment options for inflammatory bowel diseases in Russia. The results of two multicenter studies. Almanac of Clinical Medicine. 2018;46(5):445-463. (in Russ.) doi:10.18786/2072-0505-2018-46-5-445-463. @@Белоусова Е. А., Абдулганиева Д. И., Алексеева О. П. и соавт. Социально-демографическая характеристика, особенности течения и варианты лечения воспалительных заболеваний кишечника в России. Результаты двух многоцентровых исследований. Альманах клинической медицины. 2018;46(5):445-463. doi:10.18786/2072-0505-2018-46-5-445-463.
6. GBD 2017 Inflammatory Bowel Disease Collaborators. The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol Hepatol. 2020;5(1):17-30. doi:10.1016/S2468-1253(19)30333-4.
7. Ng S. C., Shi H. Y., Hamidi N., et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet. 2017;390(10114):2769-2778. doi:10.1016/S0140-6736(17)32448-0.
8. Osipenko M. F., Livzan M. A., Skalinskaya M. I., Lyalyukova E. A. Concentration of fecal calprotectin in the differential diagnosis of intestinal diseases. Therapeutic archive. 2015;87(2):30-33. (in Russ.) doi:10.17116/terarkh201587230-33 @@Осипенко М. Ф., Ливзан М. А., Скалинская М. И., Лялюкова Е. А. Концентрация фекального кальпротектина в дифференциальной диагностике заболеваний кишечника. Терапевтический архив. 2015;87(2):30-33. doi:10.17116/terarkh201587230-33
9. Olén O., Erichsen R., Sachs M. C., et al. Colorectal cancer in ulcerative colitis: a Scandinavian population-based cohort study. Lancet. 2020;395(10218):123-131. doi:10.1016/S0140-6736(19)32545-0.
10. Eaden J. A., Abrams K. R., Mayberry J. F. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut. 2001;48(4):526-35. doi:10.1136/gut.48.4.526.
11. Lutgens M. W., van Oijen M. G., van der Heijden G. J., et al. Declining risk of colorectal cancer in inflammatory bowel disease: an updated meta-analysis of population-based cohort studies. Inflamm Bowel Dis. 2013;19(4):789-99. doi:10.1097/MIB.0b013e31828029c0.
12. Choi C. H., Rutter M. D., Askari A., et al. Forty-Year Analysis of Colonoscopic Surveillance Program for Neoplasia in Ulcerative Colitis: An Updated Overview. Am J Gastroenterol. 2015;110(7):1022-34. doi:10.1038/ajg.2015.65.
13. Ivashkin V. T., Shelygin Yu.A., Khalif I. L., et al. Clinical guide of russian association of gastroenterology and russian association of coloproctology on diagnostics and treatment of ulcerative colitis. Koloproktologia. 2017;1(59):6-30. (In Russ.) @@Ивашкин В. Т., Шелыгин Ю. А., Халиф И. Л. и соавт. Клинические рекомендации Российской Гастроэнтерологической Ассоциации и Ассоциации Колопроктологов России по диагностике и лечению язвенного колита. Колопроктология. 2017;1(59):6-30.
14. Shergill A. K., Lightdale J. R., Bruining D. H., et al. The role of endoscopy in inflammatory bowel disease. Gastrointest Endosc. 2015;81(5):1101-21.e1-13. doi:10.1016/j.gie.2014.10.030.
15. Annese V., Daperno M., Rutter M. D., et al. European Crohn’s and Colitis Organisation. European evidence based consensus for endoscopy in inflammatory bowel disease. J Crohns Colitis. 2013;7(12):982-1018. doi:10.1016/j.crohns.2013.09.016.
16. Rex D. K., Boland C. R., Dominitz J. A., et al. Colorectal Cancer Screening: Recommendations for Physicians and Patients from the U. S. Multi-Society Task Force on Colorectal Cancer. Gastroenterology. 2017;153(1):307-323. doi:10.1053/j.gastro.2017.05.013.
17. Rubin D. T., Ananthakrishnan A. N., Siegel C. A., et al. ACG Clinical Guideline: Ulcerative Colitis in Adults. Am J Gastroenterol. 2019;114(3):384-413. doi:10.14309/ajg.0000000000000152.
18. Farraye F. A., Odze R. D., Eaden J., Itzkowitz S. H. AGA technical review on the diagnosis and management of colorectal neoplasia in inflammatory bowel disease. Gastroenterology. 2010;138(2):746-74,774.e1-4; quiz e12-3. doi:10.1053/j.gastro.2009.12.035.
19. Cairns S. R., Scholefield J. H., Steele R. J., et al. British Society of Gastroenterology; Association of Coloproctology for Great Britain and Ireland. Guidelines for colorectal cancer screening and surveillance in moderate and high risk groups (update from 2002). Gut. 2010;59(5):666-89. doi:10.1136/gut.2009.179804.
20. Magro F., Gionchetti P., Eliakim R., et al. European Crohn’s and Colitis Organisation [ECCO]. Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 1: Definitions, Diagnosis, Extra-intestinal Manifestations, Pregnancy, Cancer Surveillance, Surgery, and Ileo-anal Pouch Disorders. J Crohns Colitis. 2017;11(6):649-670. doi:10.1093/ecco-jcc/jjx008.
21. Lamb C. A., Kennedy N. A., Raine T., et al. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut. 2019;68(Suppl 3): s1-s106. doi:10.1136/gutjnl-2019-318484.
22. Sebastian S., Hernández V., Myrelid P., et al. Colorectal cancer in inflammatory bowel disease: results of the 3rd ECCO pathogenesis scientific workshop (I). J Crohns Colitis. 2014;8(1):5-18. doi:10.1016/j.crohns.2013.04.008.
23. Jess T., Simonsen J., Jørgensen K. T., et al. Decreasing risk of colorectal cancer in patients with inflammatory bowel disease over 30 years. Gastroenterology. 2012;143(2):375-81.e1; quiz e13-4. doi:10.1053/j.gastro.2012.04.016.
24. Kappelman M. D., Farkas D. K., Long M. D., et al. Risk of cancer in patients with inflammatory bowel diseases: a nationwide population-based cohort study with 30 years of follow-up evaluation. Clin Gastroenterol Hepatol. 2014;12(2):265-73.e1. doi:10.1016/j.cgh.2013.03.034.
25. Ekbom A., Helmick C., Zack M., Adami H. O. Ulcerative colitis and colorectal cancer. A population-based study. N Engl J Med. 1990;323(18):1228-33. doi:10.1056/NEJM199011013231802.
26. Chouhan H., Ferrandon S., DeVecchio J., et al. A Changing Spectrum of Colorectal Cancer Biology with Age: Implications for the Young Patient. Dis Colon Rectum. 2019;62(1):21-26. doi:10.1097/DCR.0000000000001188.
27. Van Der Kraak L., Gros P., Beauchemin N. Colitis-associated colon cancer: Is it in your genes?. World J Gastroenterol. 2015;21(41):11688-11699. doi:10.3748/wjg.v21.i41.11688.
28. Rutter M., Saunders B., Wilkinson K., et al. Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology. 2004; 126(2):451-9. doi:10.1053/j.gastro.2003.11.010.
29. Kirchgesner J., Svrcek M., Le Gall G., et al. Saint-Antoine Inflammatory Bowel Disease Network. Nancy Index Scores of Chronic Inflammatory Bowel Disease Activity Associate with Development of Colorectal Neoplasia. Clin Gastroenterol Hepatol. 2020;18(1):150-157.e1. doi:10.1016/j.cgh.2019.05.002.
30. Knyazev O. V., Kagramanova A. V., Khomeriki S. G., Parfenov A. I. Is histological remission of ulcerative colitis achievable? Terapevticheskii arkhiv. 2021;93(8):975-981. (In Russ.). doi:10.26442/00403660.2021.08.200981. @@Князев О. В., Каграманова А. В., Хомерики С. Г., Парфенов А. И. Достижима ли гистологическая ремиссия язвенного колита? Терапевтический архив. 2021;93(8):975-981. doi:10.26442/00403660.2021.08.200981.
31. Söderlund S., Granath F., Broström O., et al. Inflammatory bowel disease confers a lower risk of colorectal cancer to females than to males. Gastroenterology. 2010;138(5):1697-703. doi:10.1053/j.gastro.2010.02.007.
32. Wijnands A. M., de Jong M. E., Lutgens M. W.M.D., et al. Prognostic Factors for Advanced Colorectal Neoplasia in Inflammatory Bowel Disease: Systematic Review and Meta-analysis. Gastroenterology. 2021;160(5):1584-1598. doi:10.1053/j.gastro.2020.12.036.
33. Hou J. K., Kramer J. R., Richardson P., et al. Risk of colorectal cancer among Caucasian and African American veterans with ulcerative colitis. Inflamm Bowel Dis. 2012;18(6):1011-7. doi:10.1002/ibd.21840.
34. Jess T., Rungoe C., Peyrin-Biroulet L. Risk of colorectal cancer in patients with ulcerative colitis: a meta-analysis of population-based cohort studies. Clin Gastroenterol Hepatol. 2012;10(6):639-45. doi:10.1016/j.cgh.2012.01.010.
35. Ekbom A., Helmick C., Zack M., Adami H. O. Increased risk of large-bowel cancer in Crohn’s disease with colonic involvement. Lancet. 1990;336(8711):357-9. doi:10.1016/0140-6736(90)91889-i.
36. Baars J. E., Kuipers E. J., van Haastert M., et al. Age at diagnosis of inflammatory bowel disease influences early development of colorectal cancer in inflammatory bowel disease patients: a nationwide, long-term survey. J Gastroenterol. 2012;47(12):1308-22. doi:10.1007/s00535-012-0603-2.
37. Zhou Q., Shen Z. F., Wu B. S., et al. Risk of Colorectal Cancer in Ulcerative Colitis Patients: A Systematic Review and Meta-Analysis. Gastroenterol Res Pract. 2019;2019:5363261. doi:10.1155/2019/5363261.
38. Vedamurthy A., Ananthakrishnan A. N. Influence of Environmental Factors in the Development and Outcomes of Inflammatory Bowel Disease. Gastroenterol Hepatol (N Y). 2019;15(2):72-82. URL: https://pubmed.ncbi.nlm.nih.gov/31011301.
39. Botteri E., Iodice S., Raimondi S., et al. Cigarette smoking and adenomatous polyps: a meta-analysis. Gastroenterology. 2008;134(2):388-95. doi:10.1053/j.gastro.2007.11.007.
40. Van der Sloot K. W.J., Tiems J. L., Visschedijk M. C., et al. Cigarette Smoke Increases Risk for Colorectal Neoplasia in Inflammatory Bowel Disease. Clin Gastroenterol Hepatol. 2022;20(4):798-805.e1. doi:10.1016/j.cgh.2021.01.015
41. Soetikno R. M., Lin O. S., Heidenreich P. A., et al. Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis: a meta-analysis. Gastrointest Endosc. 2002;56(1):48-54. doi:10.1067/mge.2002.125367.
42. Cremer A., Demetter P., De Vos M., et al. Belgian Inflammatory Bowel Disease Research and Development (BIRD) Group. Risk of Development of More-advanced Lesions in Patients with Inflammatory Bowel Diseases and Dysplasia. Clin Gastroenterol Hepatol. 2020;18(7):1528-1536.e5. doi:10.1016/j.cgh.2019.05.062.
43. Samadder N. J., Valentine J. F., Guthery S., et al. Family History Associates with Increased Risk of Colorectal Cancer in Patients with Inflammatory Bowel Diseases. Clin Gastroenterol Hepatol. 2019;17(9):1807-1813.e1. doi:10.1016/j.cgh.2018.09.038.
44. De Jong M. E., Van Tilburg S. B., Nissen L. H.C., et al. Long-term Risk of Advanced Neoplasia After Colonic Low-grade Dysplasia in Patients with Inflammatory Bowel Disease: A Nationwide Cohort Study. J Crohns Colitis. 2019;13:1485-91. doi:10.1093/ecco-jcc/jjz114.
45. Keller D. S., Windsor A., Cohen R., Chand M. Colorectal cancer in inflammatory bowel disease: review of the evidence. Tech Coloproctol. 2019;23(1):3-13. doi:10.1007/s10151-019-1926-2.
46. Brentnall T. A., Crispin D. A., Rabinovitch P. S., et al. Mutations in the p53 gene: an early marker of neoplastic progression in ulcerative colitis. Gastroenterology. 1994;107(2):369-78. doi:10.1016/0016-5085(94)90161-9.
47. Kolodej E. N. Ulcerative colitis and colon cancer. the present-day and open questions of diagnostics. Medical almanac. 2013;1(25):74-78. (In Russ.) @@Колодей Е. Н. Язвенный колит и рак толстой кишки: актуальные и нерешенные вопросы диагностики. Медицинский альманах. 2013;1(25):74-78.
Review
For citations:
Bikbavova G.R., Livzan M.A., Fedorin M.M. Risk factors for colorectal cancer in IBD patients. Experimental and Clinical Gastroenterology. 2022;(9):140-146. (In Russ.) https://doi.org/10.31146/1682-8658-ecg-205-9-140-146
Views:
446
Email this article 